# The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

> **NCT06102707** · NA · NOT_YET_RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 50 (estimated)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** Fluzopril Combined With Apatinib

## Key facts

- **NCT ID:** NCT06102707
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06102707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06102707, "The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06102707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*